Beijing Aosaikang Pharmaceutical Co., Ltd. (SHE:002755)
China · Delayed Price · Currency is CNY 16.21
+0.96 (6.30%)
Apr 29, 2026, 3:04 PM CST
SHE:002755 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,752 | 1,779 | 1,741 | 1,430 | 1,859 | 3,041 |
Other Revenue | - | - | 37.05 | 13.77 | 13.61 | 65.22 |
| 1,752 | 1,779 | 1,778 | 1,443 | 1,873 | 3,107 | |
Revenue Growth (YoY) | -4.65% | 0.08% | 23.15% | -22.92% | -39.72% | -17.87% |
Cost of Revenue | 339.5 | 351.87 | 333.53 | 277.51 | 245.7 | 277.05 |
Gross Profit | 1,413 | 1,427 | 1,444 | 1,166 | 1,627 | 2,830 |
Selling, General & Admin | 1,005 | 1,047 | 1,151 | 973.24 | 1,333 | 2,159 |
Research & Development | 125.85 | 158.61 | 177.32 | 472.01 | 588.84 | 324.45 |
Other Operating Expenses | -15.89 | -15.72 | 21.83 | 15.67 | 24.89 | 41.19 |
Operating Expenses | 1,115 | 1,190 | 1,350 | 1,456 | 1,940 | 2,520 |
Operating Income | 298.02 | 236.77 | 94.55 | -290.49 | -313.2 | 309.73 |
Interest Expense | - | - | -2.64 | -2.81 | -2.76 | -3.99 |
Interest & Investment Income | 0.34 | - | 30.99 | 26.78 | 39.89 | 43.72 |
Currency Exchange Gain (Loss) | - | - | 1.37 | 0.96 | 0.07 | -0.02 |
Other Non Operating Income (Expenses) | 14.25 | 12.13 | -1.8 | -3.19 | -1.89 | -0.08 |
EBT Excluding Unusual Items | 312.61 | 248.9 | 122.46 | -268.75 | -277.89 | 349.36 |
Gain (Loss) on Sale of Investments | 5.34 | 5.66 | 12.73 | 12.5 | 1.68 | 2.39 |
Gain (Loss) on Sale of Assets | -0.01 | -0.03 | -0.03 | 0.03 | 0.21 | 0.3 |
Asset Writedown | -3.81 | -1.44 | -3.06 | -5.7 | -20.79 | -0.86 |
Other Unusual Items | - | - | 19.35 | 60.99 | 34.29 | 54.87 |
Pretax Income | 314.12 | 253.09 | 151.45 | -200.93 | -262.5 | 406.07 |
Income Tax Expense | 47.55 | 39.38 | 22.98 | 6.55 | 3.7 | 25.51 |
Earnings From Continuing Operations | 266.57 | 213.72 | 128.47 | -207.48 | -266.21 | 380.56 |
Minority Interest in Earnings | -0.23 | 22.89 | 31.82 | 58.95 | 40.38 | -0.66 |
Net Income | 266.34 | 236.6 | 160.29 | -148.53 | -225.83 | 379.91 |
Net Income to Common | 266.34 | 236.6 | 160.29 | -148.53 | -225.83 | 379.91 |
Net Income Growth | 45.16% | 47.60% | - | - | - | -47.35% |
Shares Outstanding (Basic) | 953 | 946 | 943 | 928 | 941 | 927 |
Shares Outstanding (Diluted) | 953 | 946 | 943 | 928 | 941 | 927 |
Shares Change (YoY) | 4.95% | 0.37% | 1.57% | -1.34% | 1.55% | 0.16% |
EPS (Basic) | 0.28 | 0.25 | 0.17 | -0.16 | -0.24 | 0.41 |
EPS (Diluted) | 0.28 | 0.25 | 0.17 | -0.16 | -0.24 | 0.41 |
EPS Growth | 38.32% | 47.06% | - | - | - | -47.44% |
Free Cash Flow | 355.88 | 508.07 | 180.94 | -155.89 | -203.27 | 433.95 |
Free Cash Flow Per Share | 0.37 | 0.54 | 0.19 | -0.17 | -0.22 | 0.47 |
Dividend Per Share | - | - | 0.120 | - | - | 0.100 |
Dividend Growth | - | - | - | - | - | -50.00% |
Gross Margin | 80.63% | 80.22% | 81.24% | 80.77% | 86.88% | 91.08% |
Operating Margin | 17.01% | 13.31% | 5.32% | -20.13% | -16.73% | 9.97% |
Profit Margin | 15.20% | 13.30% | 9.02% | -10.29% | -12.06% | 12.23% |
Free Cash Flow Margin | 20.31% | 28.56% | 10.18% | -10.80% | -10.85% | 13.97% |
EBITDA | 437.15 | 363.13 | 169.84 | -208.79 | -224.03 | 401.33 |
EBITDA Margin | 24.95% | 20.41% | 9.55% | -14.46% | -11.96% | 12.92% |
D&A For EBITDA | 139.13 | 126.37 | 75.3 | 81.7 | 89.17 | 91.6 |
EBIT | 298.02 | 236.77 | 94.55 | -290.49 | -313.2 | 309.73 |
EBIT Margin | 17.01% | 13.31% | 5.32% | -20.12% | -16.73% | 9.97% |
Effective Tax Rate | 15.14% | 15.56% | 15.17% | - | - | 6.28% |
Revenue as Reported | - | - | 1,778 | 1,443 | 1,873 | 3,107 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.